3Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer [ J ]. J Clin Oncol, 2009, 27 (36) : 6251-6266.
4Pennycooke M, Chaudary N, Shuralyova I, et al. Differential expression of human nueleoside transporters in normal and tumor tissue [ J ]. Biochem Biophys Res Commun, 2001, 280(3): 951-959.
5Oguri T, Achiwa H, Muramatsu H, et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer [ J]. Cancer Letters, 2007, 256 (1) : 112-119.
6Achiwa H, Oguri T, Sato S, et al. Determinants of sensitivity and resistance to gemcitabine : the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer [J]. Cancer Sci, 2004, 95 (9): 753 - 757.
7Hopper-Borge E, Xu X, Shen T, et al. Human muhidrug resistance protein 7 ( ABCC10 ) is a resistance factor for nucleoside analogues and epothilone B[J]. Cancer Res, 2009, 69(1) : 178-184.
8Ikeda R, Vermeulen LC, Lau E, et al. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells [J]. IntJOncol, 2011, 38(2):513-519.
9Furusawa S, Wu J. The effects of biscoclaurine alkaloid cepharanthine on mammalian ceils: implications for cancer, shock, and inflammatory diseases[J]. Life Sci, 2007, 80(12) : 1073-1079.
10Engelman JA, Chu C, Lin A, et al. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain [ J ]. FEBS Lett, 1998, 428 (3) : 205-211.
二级参考文献19
1Korpanty G, Smyth E, Carney DN. Update on anti-angiogenic therapyin non-small cell lung cancer : Are we making progress. [ J ]. JThorac Dis, 2011, 3(1) : 19-29.
3Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer inchronic obstructive pulmonary disease. A prospective, matched,controlled study[ J] . Ann Intern Med, 1986, 105 : 503-507.
4Anthonisen NR,Skeans MA,Wise +RA,et al. The effects of a smokingcessation intervention on 14.5 -year mortality : a randomized clinicaltrial[ J]. Ann Intern Med, 2005,142(4) : 233-239.
5Yang IA, Relan V,Wright CM, et al. Common pathogenic mechanismsand pathways in the development of COPD and lung cancer [ J ].Expert Opin Ther Targets, 2011,15(4) : 439-456.
6Yu YH, Liao CC, Hsu WH, et al. Increased lung cancer riskamong patients with pulmonary tuberculosis : a population cohortstudy[ J]. J Thorac oncol, 2011, 6(1): 32-37.
6Funai K, Takamochi K, Itaya T,et al. Feasibility study of adju-vant chemotherapy with gemcitabine and split-dose cisplatin forcompletely resected non-small-cell lung cancer[ J]. Lung Cancer,2010,63(5):223-230.
7Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going. [ J ]. Ann Oncol, 2010,21 Suppl7:viil96-198.
8Tibaldi C, Mazzoni E, Arcabasso G, et al. Cisplatin plus gemcit-abine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study [ J ]. Clin Lung Cancer, 2009,10(1) :53-57.
9Funai K, Takamochi K, Itaya T, et al. Feasibility study of adju-vant chemotherapy with gemcitabine and split-dose cisplatin forcompletely resected non-small-cell lung cancer[ J]. Lung Cancer,2010,68(1) :78-83.
